167 related articles for article (PubMed ID: 38165303)
1. Identifying Genetic Risk for Amyloid-Related Imaging Abnormalities.
Hardy J; Schott JM
Neurology; 2024 Feb; 102(3):e208096. PubMed ID: 38165303
[TBL] [Abstract][Full Text] [Related]
2. Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy.
Barakos J; Purcell D; Suhy J; Chalkias S; Burkett P; Marsica Grassi C; Castrillo-Viguera C; Rubino I; Vijverberg E
J Prev Alzheimers Dis; 2022; 9(2):211-220. PubMed ID: 35542992
[TBL] [Abstract][Full Text] [Related]
3. Subcortical signal alteration of corticospinal tracts. A radiologic manifestation of ARIA: A case report.
Sotoudeh H; Alizadeh M; Shahidi R; Shobeiri P; Love N; Singhal A
Radiol Case Rep; 2023 Jan; 18(1):275-279. PubMed ID: 36388611
[TBL] [Abstract][Full Text] [Related]
4. Amyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review.
Filippi M; Cecchetti G; Spinelli EG; Vezzulli P; Falini A; Agosta F
JAMA Neurol; 2022 Mar; 79(3):291-304. PubMed ID: 35099507
[TBL] [Abstract][Full Text] [Related]
5. Association of Microglial Activation With Spontaneous ARIA-E and CSF Levels of Anti-Aβ Autoantibodies.
Piazza F; Caminiti SP; Zedde M; Presotto L; DiFrancesco JC; Pascarella R; Giossi A; Sessa M; Poli L; Basso G; Perani D
Neurology; 2022 Sep; 99(12):e1265-e1277. PubMed ID: 35940900
[TBL] [Abstract][Full Text] [Related]
6. Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities.
Söderberg L; Johannesson M; Gkanatsiou E; Nygren P; Fritz N; Zachrisson O; Rachalski A; Svensson AS; Button E; Dentoni G; Osswald G; Lannfelt L; Möller C
Sci Rep; 2024 May; 14(1):10868. PubMed ID: 38740836
[TBL] [Abstract][Full Text] [Related]
7. The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.
Wu W; Ji Y; Wang Z; Wu X; Li J; Gu F; Chen Z; Wang Z
Eur J Med Res; 2023 Nov; 28(1):544. PubMed ID: 38017568
[TBL] [Abstract][Full Text] [Related]
8. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
[TBL] [Abstract][Full Text] [Related]
9. Amyloid-related Imaging Abnormalities in Alzheimer Disease Treated with Anti-Amyloid-β Therapy.
Agarwal A; Gupta V; Brahmbhatt P; Desai A; Vibhute P; Joseph-Mathurin N; Bathla G
Radiographics; 2023 Sep; 43(9):e230009. PubMed ID: 37651273
[TBL] [Abstract][Full Text] [Related]
10. Amyloid-Related Imaging Abnormalities: An Update.
Roytman M; Mashriqi F; Al-Tawil K; Schulz PE; Zaharchuk G; Benzinger TLS; Franceschi AM
AJR Am J Roentgenol; 2023 Apr; 220(4):562-574. PubMed ID: 36321981
[TBL] [Abstract][Full Text] [Related]
11. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics.
Hampel H; Elhage A; Cho M; Apostolova LG; Nicoll JAR; Atri A
Brain; 2023 Nov; 146(11):4414-4424. PubMed ID: 37280110
[TBL] [Abstract][Full Text] [Related]
12. MR imaging features of amyloid-related imaging abnormalities.
Barakos J; Sperling R; Salloway S; Jack C; Gass A; Fiebach JB; Tampieri D; Melançon D; Miaux Y; Rippon G; Black R; Lu Y; Brashear HR; Arrighi HM; Morris KA; Grundman M
AJNR Am J Neuroradiol; 2013 Oct; 34(10):1958-65. PubMed ID: 23578674
[TBL] [Abstract][Full Text] [Related]
13. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects.
Villain N; Planche V; Levy R
Rev Neurol (Paris); 2022 Dec; 178(10):1011-1030. PubMed ID: 36184326
[TBL] [Abstract][Full Text] [Related]
14. Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.
Honig LS; Sabbagh MN; van Dyck CH; Sperling RA; Hersch S; Matta A; Giorgi L; Gee M; Kanekiyo M; Li D; Purcell D; Dhadda S; Irizarry M; Kramer L
Alzheimers Res Ther; 2024 May; 16(1):105. PubMed ID: 38730496
[TBL] [Abstract][Full Text] [Related]
15. Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?
Piazza F; Winblad B
J Alzheimers Dis; 2016 Mar; 52(2):417-20. PubMed ID: 27031492
[TBL] [Abstract][Full Text] [Related]
16. Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease.
Withington CG; Turner RS
Front Neurol; 2022; 13():862369. PubMed ID: 35401412
[TBL] [Abstract][Full Text] [Related]
17. Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti-β-Amyloid Immunotherapy: A Meta-analysis.
Jeong SY; Suh CH; Shim WH; Lim JS; Lee JH; Kim SJ
Neurology; 2022 Nov; 99(19):e2092-e2101. PubMed ID: 36038268
[TBL] [Abstract][Full Text] [Related]
18. Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis.
Arrighi HM; Barakos J; Barkhof F; Tampieri D; Jack C; Melançon D; Morris K; Ketter N; Liu E; Brashear HR
J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):106-12. PubMed ID: 25669746
[TBL] [Abstract][Full Text] [Related]
19. Amyloid-Related Imaging Abnormalities in an Aged Squirrel Monkey with Cerebral Amyloid Angiopathy.
Heuer E; Jacobs J; Du R; Wang S; Keifer OP; Cintron AF; Dooyema J; Meng Y; Zhang X; Walker LC
J Alzheimers Dis; 2017; 57(2):519-530. PubMed ID: 28269776
[TBL] [Abstract][Full Text] [Related]
20. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.
Salloway S; Chalkias S; Barkhof F; Burkett P; Barakos J; Purcell D; Suhy J; Forrestal F; Tian Y; Umans K; Wang G; Singhal P; Budd Haeberlein S; Smirnakis K
JAMA Neurol; 2022 Jan; 79(1):13-21. PubMed ID: 34807243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
